桌面
添加运营动脉到电脑桌面
安装后将用独立窗口打开,并可在电脑桌面快捷访问
足迹
浏览记录
加载中...
查看更多

2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页

2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页 复制标题
2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页_第1页
1/28页
2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页_第2页
2/28页
2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页_第3页
3/28页
2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页_第4页
4/28页
2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页_第5页
5/28页
2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页_第6页
6/28页
2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页_第7页
7/28页
2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页_第8页
8/28页
2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页_第9页
9/28页
2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页_第10页
10/28页
来源:发现报告(www.fxbaogao.com/view?id=5788630)| 引用请注明出处White PaperTargeting Residual Risk: The Next Wave of Cardiovascular, Renal and Metabolic Innovation Beyond obesity, a strategic outlook on the CVRM pipeline, market and routes to commercial successMARKUS GORES, Vice President, Thought Leadership, IQVIASTEFAN LUTZMAYER, Senior Consultant, Thought Leadership, IQVIASOPHIE MARLOW, Summer Intern, Thought Leadership, IQVIA来源:发现报告(www.fxbaogao.com/view?id=5788630)| 引用请注明出处Table of contentsIntroduction 1The CVRM opportunity: Unmet need, and complexity, continue to rise 2The unique complexity of the CVRM opportunity 3The CVRM pipeline and innovation highlights 5The competitive landscape in CVRM 7Deep dive: CVRM innovation highlights 9I. Dyslipidaemias 9II. Hypertension 13Outlook for the CVRM market 16How to succeed as CVRM innovator 18About the authors 20References 21来源:发现报告(www.fxbaogao.com/view?id=5788630)| 引用请注明出处 iqvia.com | 1IntroductionSince the publication of our white paper ‘A renaissance for cardiometabolic innovation’ in 2023, the biopharmaceutical industry’s renewed interest in an area it had largely neglected for much of the previous two decades has yielded some remarkable breakthroughs.1Incretin-based pharmacotherapies have truly transformed weight management, unleashed extraordinary consumer demand and propelled obesity up the ranks to become the fourth largest therapy area by value, generating $66Bn in global sales in 2025, at ex-manufacturer prices.Meanwhile, Madrigal made history in March 2024 when the FDA approved its oral, thyroid hormone receptor beta agonist Rezdiffra as the first therapy for metabolic dysfunction-associated steatohepatitis (MASH), which had become a notorious graveyard for drug development.In May 2026, AstraZeneca’s Baxfendy was approved for the treatment of hypertension, introducing the first aldosterone synthase inhibitor to this market and bringing hope to the many patients inadequately served by existing therapy options.These examples clearly illustrate that innovation focused on cardiovascular-renal-metabolic (CVRM) diseases is alive and well and delivers transformational benefits for patients.But there is more to do. CVRM risk factors continue to be among the leading drivers of both global mortality and the burden of disease and thus represent key targets for effectively managing population health.In this white paper, we will explore the latest trends in CVRM innovation, including a deep dive into selected therapeutic breakthroughs, and provide an outlook on the competitive landscape and the CVRM market opportunity.Since obesity, understandably, is often the centre of attention and extensively covered in many reviews, we will focus in this white paper on ex-obesity CVRM innovation, while acknowledging the interdependencies with obesity therapies as they impact a range of CVRM risk factors beyond BMI.来源:发现报告...

1、当您付费下载文档后,您只拥有了使用权限,并不意味着购买了版权,文档只能用于自身使用,不得用于其他商业用途(如 [转卖]进行直接盈利或[编辑后售卖]进行间接盈利)。
2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。
3、如文档内容存在违规,或者侵犯商业秘密、侵犯著作权等,请点击“违规举报”。

查找下载文件的指引

一、电脑端

- Windows 系统:按下键盘快捷键 `Ctrl + J`,即可打开下载列表。  

- Mac 系统:按下键盘快捷键 `⌘ + J`,即可打开下载列表。  

二、手机端

1. 打开手机浏览器,点击浏览器右下角的 “≡”(或“更多”)图标。  

2. 在弹出的菜单中找到并点击 “下载内容”(或类似选项),即可查看已下载的文件。  

提示:不同浏览器界面略有差异,若未找到“下载”入口,可尝试在浏览器设置中搜索“下载”关键词。


2025-艾昆纬_靶向残余风险:心血管、肾脏和代谢创新的下一波浪潮:超越肥胖,对CVRM管线、市场及商业成功的战略展望-26页

¥9.9
会员免费
下载本文档
安全支付  |  可重复下载
格式pdf
大小3.99 MB
页数约28页
下载16 次
萤火报告 + 关注
实名认证
确认删除?
会员
教程
联系
  • 站长微信
顶部